Evidence map›Paper›PMID 34876055›Full record

ArticleBMC cancer2021

Degradation of skeletal mass in locally advanced oesophageal cancer between initial diagnosis and recurrence.

Yacine Zouhry, Abdelkader Taibi, Sylvaine Durand-Fontanier, Tiffany Darbas, Geraud Forestier, Jacques Monteil, Valérie Lebrun-Ly, Philippe Fayemendy, Sophie Leobon, Pierre Jesus and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 51% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Yacine ZouhryMedical Oncology Department, Limoges University Hospital, 2 avenue Martin Luther King, 87042, Limoges, France.
Abdelkader TaibiDigestive Surgery Department, Limoges University Hospital, 2 avenue Martin Luther King, 87042, Limoges, France.
Sylvaine Durand-FontanierDigestive Surgery Department, Limoges University Hospital, 2 avenue Martin Luther King, 87042, Limoges, France.
Tiffany DarbasMedical Oncology Department, Limoges University Hospital, 2 avenue Martin Luther King, 87042, Limoges, France.
Geraud ForestierNeuroradiology Department, Limoges University Hospital, 2 avenue Martin Luther King, 87042, Limoges, France.
Jacques MonteilNuclear Medicine Department, Limoges University Hospital, 2 avenue Martin Luther King, 87042, Limoges, France.
Valérie Lebrun-LyMedical Oncology Department, Limoges University Hospital, 2 avenue Martin Luther King, 87042, Limoges, France.
Philippe FayemendyNutrition Unit, Limoges University Hospital, 2 avenue Martin Luther King, 87042, Limoges, France.
Sophie LeobonMedical Oncology Department, Limoges University Hospital, 2 avenue Martin Luther King, 87042, Limoges, France.
Pierre JesusMedical Oncology Department, Limoges University Hospital, 2 avenue Martin Luther King, 87042, Limoges, France.
Elise DelucheMedical Oncology Department, Limoges University Hospital, 2 avenue Martin Luther King, 87042, Limoges, France. elise.deluche@chu-limoges.fr.
Université de Limoges · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe prognostic value of a low skeletal mass index (SMI) has been investigated in locally advanced oesophageal (LAE) cancer at diagnosis. However, nothing is known about its evolution and clinical impact between initial diagnosis and recurrence.

methodsA total of 89 patients treated for LAE cancer between January 2009 and December 2019 were included in this study. Computed tomography (CT) scans before treatment and at recurrence were evaluated. SMI and other body composition parameters were analysed by the L3 scan method.

resultsParticipants were aged 66.0 (36.0-86) years. The incidence of low SMI increased by 12.3% between diagnosis and recurrence (70.7% vs. 83.0%, respectively) over a median follow-up of 16.9 (1.7-101.6) months. Patients with high SMI at diagnosis showed loss of muscle mass (58.0 vs. 55.2 cm

conclusionsThe percentage of patients with a low SMI increased during follow-up. Our data suggest that an assessment of skeletal muscle parameters and nutrition support may be more useful in patients with a high SMI.

Indexed as

AdultAgedAged, 80 and overBody CompositionBody Mass IndexEsophageal NeoplasmsFemaleFollow-Up StudiesHumansIncidenceMaleMiddle AgedMuscle, SkeletalNeoplasm Recurrence, LocalPrognosisProportional Hazards ModelsNutritionOesophageal cancerOutcomeSkeletal muscle mass

Identifiers

PMID34876055
PMCPMC8653570
OpenAlexW4200225227

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.